Final 2020 CMS Outpatient, ASC Payment Rules Broaden Patient Access To Medtech
Executive Summary
The US Medicare agency is allowing more device procedures to be conducted at outpatient hospitals and ambulatory surgical centers (ASC), while approving several new devices for passthrough payments for three years under its Outpatient Prospective Payment System and ASC payment system final rule for 2020, released on 1 November.
You may also be interested in...
Procept BioRobotics Seeks $164M To Go Public
The company is selling 6,556,000 shares at $25 a share to support the commercialization of its AquaBeam robotic system for minimally invasive treatment of benign prostatic hyperplasia.
Medtech Companies Must Adjust To Growth Of Outpatient Centers, ZS Consultant Advises
The medtech industry has been slow to adapt to the rapid growth of lower-cost outpatient centers that are taking procedures out of hospitals, according to Brian Chapman, a consultant for ZS.
Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market
Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.